FXI - double bottom at Fibo levelBreaking out of its downtrend line, after a double bottom at the 61.8 retracement level of the Feb'16-Jan'18 advance.
Largecap
Teradyne - Robotics & mobile test equipment buy at $30Teradyne is a mobile test equipment and robotics company, which are both growth CAGR area's over 24% in coming year and coming near full fibonacci retrenchment from June 2017. Current price is $31 and 29.88 was 2017 low, or round $30 entry. Can't see it going below this. TER IRBT NASDAQ:BRKS are a few other robotic stocks on NYSE.
About:
Teradyne, Inc. supplies automation equipment for test and industrial applications. The Company designs, develops, manufactures and sells automatic test systems used to test semiconductors, wireless products, data storage and complex electronics systems in the consumer electronics, wireless, automotive, industrial, communications, and aerospace and defense industries. Its segments include Semiconductor Test, which includes operations related to the design, manufacturing and marketing of semiconductor test products and services; System Test, which includes operations related to the design, manufacturing and marketing of products and services for defense/aerospace instrumentation test, storage test and circuit-board test; Wireless Test, which includes operations related to the design, manufacturing and marketing of wireless test products and services, and Industrial Automation, which includes operations related to the design, manufacturing and marketing of collaborative robots. Acquired high growth EU robotics company in last 5 years.
Div. Yield: 1.1%
Mkt Value: 6.0B Bottom of Large cap and room to grow.
Ent. Value: 5.2B and another reason hair below $30 expected before resistance.
Viewers come to own decisions, this is for own use and comment as you see fit. Most don't, so if you're reading, post a comment or a like.
@pokethebear 95% stocks, <5% crypto mining & futures, Sector focus mostly small-mid cap, some large.
NASDAQ Biotech ETF (IBB) - Bullish Breakout Options TradeOn Friday's Options Action, the crew analyzed the performance of the biotech sector. The NASDAQ Biotech ETF (IBB) that tracks the large cap names have underperformed the overall sector recently. IBB has recently formed both a long term cup & handle formation and an inverted head & shoulders, a bullish setup. Coupled the largest 5 names in this ETF reporting earnings this week, provides a potential catalyst for the ETF to break higher. Expecting IBB to breakout to the upside, Michael Khouw suggests buying a Sept 113/119/125 Call Spread Risk Reversal for a $0.70 Debit. As of Friday's close, this spread is trading at $0.65.
We've structured this trade in OptionsPlay so you can analyze and view this trade along with the supporting technical chart at your convenience.
View this OptionsPlay on IBB - app.optionsplay.com
Cost: $65
Max Reward: $535
Max Risk: $11,365
POP: 43.18%
Breakeven: $119.65
Days to Expiry: 61
T- Making a bounce off the trendline.I made this trendline pattern in November 2017 when one of my clients wanted to buy T and we bought and I advised on the trade to sell in late January when T touched the top of the trend line. Once again, T has given a golden opportunity for a 4% to 6% run between the current level to the top of the trend line. A 6% div that pays you to wait on the trade form is not a bad incentive either.
Cheers!
JNJ: another fallen giantJNJ is yet another giant trading under the 200SMA.
Even though we had a strong earnings beat last week JNJ was not protected from the dip.
When the inevitable bottom is formed, I will be looking at these large caps under the 200 for bargain buys.
Hard to say what the near term status is for JNJ, following that of the market.
I would be looking for buys in the $122 range.
IBM a good opportunityThe latest data has beaten the expectations of analysts
and is in oversell condition
it's a great opportunity to insert a large company in portfolio
Valeant Pharma: Moving back downVRX may, at first glance, look like the bloodshed is over and is moving to recovery. Not just yet. The daily MACD and StochRSI are inching toward sell indicators (see screenshot) and despite the markets upward movements today (Mon 12/14), VRX's recovery was pretty modest as more shareholders exit as they see the fall incoming.
Bottom line: Put options are a possability for short-term holding if you have the risk appetite. If you don't, then definitely wait to buy (back) in if you have been considering it. If you're holding this in hopes of shaving some of your losses or bought thinking it was recovery time, sell. Sometimes the most profitable thing you can do is take a loss.
VRX's financials aren't bad by any means, but they're product pipeline is pretty weak. Consider Addyi, the "female viagra": in the first month on the market only 224 rx's for it were sold. The market is very narrow since it is only considered safe in post-menopausal women who don't drink and think its pretty dramatic side-effect profile is worth the risk. VRX has even hired on a crisis-management firm in response to antipicated F.T.C action in regard to their pricing practices.
Valeant should have never reached as high as it did and now the correction is coming. VRX has been around a while but thier $31bln market cap is absurd. They have a price to earnings of 54(!), an earning per share <$2, and still have a fairly high debt-to-assets ratio. Compare those stats to Shire who is $38bln but have an earning per share of $15, and a price-to-earnings of only $12.21.
SPY short on weak technicals, bearish newsI reinstated my short on SPY this Friday at the open, after riding the first down-and-up wave of the year. My rationale:
Technicals: RSI divergence on since the early December highs; strong rejection of the Pivot point at the 205.50 area, 206 seeming to be the area of strong selling pressure. The market bounced off the Ichimoku Cloud top on Tuesday, but it seems like we are going to retest next week. Plus, my take on the two-day gap up in equities is that the price action felt more like short-covering than consistent demand for stocks.
Fundamentals: US Economy still on its way to full employment, but weak wages (-0,2% on December and only +1,7% y/y) may weigh on corporate results come earnings season, starting on Monday).
- Lots of potentially disrupting noise coming from EZ (reports of a QE program that may be smaller than market expectations),
- Greece (Grexit being discussed again before national elections scheduled for Jan 25th),
- Venezuela (fallout from the crash in Oil and political instability ahead),
- Brazil (Petrobras corruption probe continues and more companies targeted, plus OAS default and official sanction for Odebrecth).
Overall, I'm positioned to take advantage of an above-average chance of stocks to continue going into the red for the month. Initial target set at 199.75 (S1 on Fibo Pivots and short-term strong support), extension to S2 (196.15) if the news confirm the bearish sentiment. May consider staying short if the market can't lift above the Ichimoku cloud top, but will cover after hitting sub-30 on the daily RSI as the market will probably mean-revert when that happens.
Long-term I'm mixed on SPY, since remaining long the market has proven successful for so long; besides, dovish Central Bank's talk has lifted stocks on each an every dip so far, and I can't find a reason for that to change this year (so far). On the other hand, take a look at this... www.zerohedge.com
Good luck!
